CD8A and neoplasm: Hence, it might be important to determine in human tumor samples whether the nonsynonymous mutations recognized by CD4+ and CD8+ TILs are coexpressed in the same cell in patients with HNSCC and in those with CRC and whether coexpression has an impact on the efficacy of the antitumor immune response in these patients.